참고문헌
- Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306 https://doi.org/10.1634/theoncologist.8-4-303
- Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in nonsmall- cell lung cancer. Drug Saf 2004;27:1081-1092 https://doi.org/10.2165/00002018-200427140-00002
- Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006;17:372-379 https://doi.org/10.1093/annonc/mdj057
- Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005;11:417-424 https://doi.org/10.1097/00130404-200509000-00010
- Teramoto S, Yamamoto H, Ouchi Y. Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet 2003;361:1992-1993
- Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005;23:2423-2424 https://doi.org/10.1200/JCO.2005.04.055
- Topal NB, Oruc E, Gokalp G, Topal U. Atypical pulmonary metastases: radiologic appearances. Indian J Radiol Imaging 2007;17:181-185 https://doi.org/10.4103/0971-3026.34723
- Lee JC, Kim CH, Koh JS, Baek HJ, Choe DH. Lung cancer presenting as an asymptomatic pneumatocele. Intern Med 2008;47:1757-1758 https://doi.org/10.2169/internalmedicine.47.1387
- Barnardt P, du Toit J. The radiological appearance of metastatic cystic lesions. SA Journal of Radiology 2011:131-133
- Zee YK, Chin TM, Wong AS. Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer. J Clin Oncol 2009;27:e145-e146 https://doi.org/10.1200/JCO.2009.22.4501
- Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 2005;28:103-113 https://doi.org/10.2165/00002018-200528020-00002
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500 https://doi.org/10.1126/science.1099314